Background: Epicutaneous immunotherapy (EPIT) is a promising method for treating
| INTRODUCTION
Allergen-specific immunotherapy is an attractive strategy for the treatment of food allergy. 1, 2 Epicutaneous immunotherapy (EPIT) has proven efficacious in animal models [3] [4] [5] [6] and more recently in humans. [7] [8] [9] The aim of EPIT is to reduce sensitivity to an allergen (desensitization) or to abolish sensitivity altogether (tolerance or sustained unresponsiveness, defined as the continued absence or reduction of sensitivity after the completion of therapy and discontinuation of repeated allergen exposure). The mechanism of immune tolerance to allergens remains largely unknown, but preliminary studies demonstrated increased levels of allergen-specific blocking IgG antibody associated with a reduction in specific IgE levels, 3, 4 reduced recruitment of inflammatory cells such as eosinophils, 5 and prevention of sensitization to further allergens. 6 In this study, we investigated a well-characterized mouse model of peanut sensitization combined with EPIT to define epigenetic mechanisms underlying the induction of desensitization to peanut with EPIT. More precisely, the DNA methylation patterns were evaluated in the gene regulatory regions of four key transcription factors involved in T-cell lineage differentiation (Gata3 (Th2), Tbx21
(Th1), Rorc (Th17), and Foxp3 (Tregs)).
As key immune-regulatory cells, Tregs have been shown to play a pivotal role in maintaining immune tolerance following epicutaneous immunotherapy in a mouse model. 10, 11 Moreover, several studies have demonstrated that epigenetic modifications in CpG-rich regions within the FOXP3 locus are associated with stable FOXP3 expression and cell-suppressive functions of Tregs. [12] [13] [14] [15] [16] We hypothesized that Foxp3 + Tregs might play a key role in the process of immune tolerance in both animal models and humans and thus investigated epigenetic modification at the Foxp3 locus within T cells. We also evaluated whether the decrease in IgE and/or Th2 cytokines could be associated with epigenetic alterations of the Th2 key regulator Gata3. To decipher the regulation of Treg and Th2 signaling, we engaged in epigenetic analyses of specific T-cell subsets (Th1, Th2, CD62L + Tregs, and CD62L À Tregs).
Here, we identify an epigenetic signature of Th2 cells and CD62L + Tregs unique to EPIT-treated animals that could be considered for monitoring immunotherapy.
| MATERIALS AND METHODS

| Animals
Three-week-old female BALB/c mice (Charles River, Lyon, France)
were housed under standard animal husbandry conditions. All experiment was performed according to the European Community rules on animal care and with a positive evaluation from the Ethical Committee no 26 (2012-041) . Mice were acclimated for 1 week before starting the sensitization to peanut protein (PPE). Epigenetic signature with EPIT 
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| Experiment 1
In a first experiment, sensitized mice were divided into two groups, one group treated by EPIT and the other one not treated (Sham).
Epicutaneous immunotherapy was performed using the Viaskin â patch (DBV Technologies, Paris, France) loaded with 100 lg of PPE and an 8-week consecutive treatment protocol, which has previously been described ( Figure 1A) . 3, 4 Two groups of 8 mice were sacrificed after sensitization at weeks 1, 2, 4, and 8 of immunotherapy and 8 weeks after the end of immunotherapy (8 + 8 weeks).
| Experiment 2
In a second experiment, sensitized mice treated as indicated in experiment 1 were sacrificed at the end of the sensitization procedure, at the end of EPIT and 8 weeks after the end of EPIT for harvesting spleens for cell extraction and sorting of Th1, Th2, CD62L + Tregs, and CD62L À Tregs (detailed procedure in the Data S1).
| Experiment 3
In a third experiment, sensitized mice were divided into three groups, one group treated by EPIT, the second one by oral immunotherapy (OIT), and the third one not treated (Sham). Epicutaneous immunotherapy was performed as described above, and OIT was performed following the protocol published by Diozeghy et al 11 adapted from
Leonard et al 18 consisting of the administration of 1 mg of PPE the first week, 2 mg the second week, then 5 mg the 5 following weeks.
Mice were sacrificed as previously described, with groups dedicated to specific time points. In addition, 3 groups (EPIT, OIT, and Sham) were exposed to a procedure of sensitization to ovalbumin (OVA) after completing the immunotherapy phase as previously described 3, 19 and then were sacrificed 10 days after the end of sensitization to OVA.
For the two experiments, blood and spleens were collected after sacrifice to stimulate in vitro splenocytes and/or purify cell populations using magnetic beads isolation kits (Miltenyi Biotec, Paris, France).
| Experiment 4
In a fourth experiment, we applied a previously described procedure to isolate Tregs from milk-sensitized mice treated by EPIT. 6 More precisely, a group of mice were first sensitized to milk and then epi- Figure 1D and E, P < .01 for both). The methylation decrease was sustained 8 weeks after the end of treatment in spleen (P < .001) and blood (P < .01) ( Figure 1D and E). The increase Results are expressed as mean AE SD in lg/mL or in percentage of total splenocytes for Tregs and in pg/mL for cytokines. Differences between groups were analyzed by a Kruskall-Wallis test followed by Dunn's multiple comparison test, and differences between time points for the same treatment groups were analyzed by ANOVA followed by Tukey's multiple comparisons test. *P < .05, **P < .01, $ P < . Figure 4D ) and was maintained 8 weeks after the end of EPIT (P < .05; Figure 4D ). Of note, Th2 cells were the only analyzed cell subtype in which Gata3 was not methylated, promoter increased significantly during EPIT in CD4 + T cells from spleen (P < .05 at the end of treatment, Figure 5B ) and blood (P < .01
at the end of treatment, Figure 5C ), whereas the DNA methylation level of the Foxp3 TSDR decreased significantly during EPIT in spleen (P < .01 at the end of treatment, Figure 5D ) and in blood (P < .01 at the end of treatment, Figure 5E ). For EPIT, epigenetic changes were sustained after the end of the treatment (8 + 8 week, Figure 5B -E). 
(B) (C) (F) (G) (D) (E) (H) (I) F I G U R E 4 Hypermethylation of Gata3 is restricted to Th2 cells and hypomethylation to Foxp3 in CD62L + Tregs at the end of epicutaneous immunotherapy (EPIT) and 8 weeks after the end of EPIT. (A) Experimental design for the methylation analysis in T-cell compartments (Th1, Th2, and Tregs). Analysis of the methylation levels of the Gata3 promoter and the Foxp3 Treg-specific demethylated regions (TSDR) in Th1 (B and C) and Th2 cells (D and E), CD62L + Tregs (F and G), and CD62L À Tregs (H and I) isolated from spleen at week 8 (immediately after treatment) or 8 weeks after the end of EPIT (sustainability). Results are expressed as individual data, and median. Differences between groups
were analyzed by a Kruskall-Wallis test followed by Dunn's multiple comparison test. ns nonsignificant, *P < .05, **P < .01 experiment, there was no modification in the DNA methylation levels for the Tbet and Rorc promoters in spleen or blood whatever the immunotherapy treatment.
3.5 | The epigenetic signature is maintained after sensitization to a new allergen (OVA) and correlates with the absence of sensitization to OVA (nonallergen-specific effect)
The DNA methylation patterns were assessed in spleen and blood
CD4 + T cells from peanut-sensitized mice treated by EPIT, Sham or
OIT and subsequently submitted to a protocol of sensitization to OVA. During this protocol, the methylation level of the Gata3 promoter remained significantly increased in EPIT mice, compared to Sham, in the spleen (P < .05, Figure 5B ) and blood (P < .05, Figure 5C ). In parallel, the methylation degree of the Foxp3 TSDR in EPIT-treated mice remained significantly decreased, compared to Sham, in spleen (P < .05, Figure 5D ) and blood (P < .01, Figure 5C ).
Oral immunotherapy did not modify the Gata3 promoter methylation in spleen or blood (
Figure 5B-C), compared to Sham. On the contrary, during the OIT protocol of sensitization to OVA, the Foxp3 TSDR methylation level significantly decreased, compared to Sham, in spleen (P < .05, Figure 5D ) and blood (P < .05, Figure 5E ).
Specific antibodies (sIgE, sIgG1, and sIgG2a) were monitored after the sensitization to OVA as new allergen ( Figure 5F -H). sIgE and sIgG1 levels were significantly enhanced for Sham and OIT compared with EPIT (P < .01), whereas sIgG2a was significantly increased for EPIT compared with Sham and OIT (P < .01). of EPIT or OIT, 8 weeks after the end of immunotherapies (8 + 8 wk) and after sensitization to OVA. (F-H) Sera were harvested after EPIT to peanut protein (PPE) and sensitization to OVA for the EPIT, OIT, and Sham groups, to measure, respectively, IgE, IgG1, and IgG2a reactive to OVA. For methylation analyses, differences between groups were analyzed by a Kruskall-Wallis test followed by Dunn's multiple comparison test. For sera, differences between groups were analyzed by a Mann-Whitney test. Results are expressed as individual data and median. ns nonsignificant, *P < .05, **P < .01 serological response to sensitization to peanut expressed in lg/mL; (D) and (E) anaphylaxis was evaluated by measuring body temperature and the level of mMCP1 in plasma 30 min after intravenous injection of peanut solution in negative control, positive control, CD62L + Treg EPIT, and CD62L À Treg EPIT groups. Differences between groups were analyzed by a Kruskall-Wallis test followed by Dunn's multiple comparison test. Individual data and medians are plotted *P < .05, **P < .01, ***P < .001 increase in peanut-specific IgG2a was observed for these groups ( Figure 6C ). Mice with CD62L + Tregs transfer before peanut sensitization did not develop peanut-specific IgE, compared to the positive control group (P < .01, Figure 6B ), but significantly increased peanut-specific IgG2a (P < .001; Figure 6C ). The positive control and CD62L À Treg groups developed anaphylaxis during peanut challenge marked by a drop in temperature (À6°C, P < .001 vs negative control group and À5°C, P < .01 negative control group, respectively) ( Figure 6D ) and increase in plasma mMCP1 (P < .001 and P < .01 vs negative control group) ( Figure 6E ). Mice with CD62L + Treg transfer before peanut sensitization were protected from anaphylaxis compared with the positive control group (P < .001 for temperature drop and P < .01 for plasma mMCP1, Figure 6D and E).
| DISCUSSION
Epicutaneous immunotherapy is a promising treatment option for food allergy, based on animal models [3] [4] [5] and clinical trials. [7] [8] [9] A comprehensive analysis of epigenetic modifications induced by EPIT and their role in the regulation of the immune response is currently lacking. The present study, in a model of peanut-sensitized mice, shows that the induction of a unique epigenetic signature by EPIT might account for both the sustainable effect of EPIT and its ability to prevent sensitization to further allergens, as previously shown. 6 In this study, we tested whether the methylation of key transcription factors (Gata3, Tbet, Rorc, and Foxp3) is involved in the efficacy of EPIT, its sustainability, and the bystander effect. 6 Mice sensitized to peanuts have been widely used to prove the biological and clinical efficacy of EPIT. Tregs. 26, 27 Genome-wide studies in autoimmune diseases have highlighted the diverging DNA methylation patterns in disease-relevant blood cell populations, 28, 29 and the advantage of detecting larger (and more robust) methylation differences when working with cellsorted populations compared with whole blood. 30 In this study, sorted cells were not antigen-specific, which could explain some differences compared with published data. A growing body of evidence suggests that DNA methylation in combination with other epigenetic modifications such as histone modifications is critical for the development of Th2 immunity and allergic disease. 33, 34 The promoter of Gata3 is marked by both activating and repressing histone modifications, a bivalent state also reported after Th2 lineage determination, 35 which commonly goes along with a larger plasticity compared with DNA methylation at Th1/Th2 regulatory regions. 36 Interestingly, the proportion of Th2 cells in spleen was not modified by EPIT, whereas their methylation level was enhanced, suggesting a change of the phenotype of the Th2 population upon EPIT similar to what was recently observed for eosinophils in asthma and which probably correspond to a different activation state. 37 Our data suggest that changes at the Gata3 locus may dramatically influence cellular responses, including T-cell cytokine secretion and Bcell production (decrease of specific IgE). At the clinical level, DNA methylation changes in genes with direct relevance to Th2 immunity and asthma are associated with allergic asthma in innercity children 38 as well as the protective farm environment. 39 Binding sites of GATA3
are found in the promoter region of Il5 and Il13. 40 Therefore, the modulation of Gata3 could allow the simultaneous abrogation of the expression of a number of inflammatory cytokines and the decline of the excessive Th2 lineage specification. 41, 42 FOXP3 is a specific marker of Treg cells and serves as a lineage specification transcriptional factor of Treg cells. Both mice and human mutations of FOXP3 result in a complex syndrome of dysregulation and enteropathy. 43, 44 DNA methylation of promoter and gene regulatory elements of Foxp3 were shown to influence the development of regulatory T cells. 14, 45 The sustained expression of FOXP3 is critical for maintaining regulatory function, 45 and a demethylated pattern of the TSDR is a prerequisite for stable Foxp3 expression and their suppressive phenotype. 15, 46, 47 The TSDR is the region ensuring both a persistent expression and the suppressive functions, through a positive feedback mechanism, during which FOXP3 binds to its own gene. Our experiment suggests that EPIT decreased the methylation level of the Foxp3 TSDR, which is linked to the induction of Tregs observed during EPIT in a mouse model. 10 A similar demethylation of the same region has previously been reported after OIT in a small human cohort. 16 50, 52, 53 Finally, this work suggests a potential biomarker to identify patients that have responded to EPIT. Martino et al 54 suggested that DNA methylation biomarkers could be a novel diagnostic test in patients with food allergy. In our study, DNA methylation of two key genes (Gata3 and Foxp3) was modulated by EPIT and could be measured in the spleen and in blood from the 4th week of EPIT onward, without analyzing antigen-specific cells.
Although we identified strong associations between DNA methylation changes at the Gata3 promoter and in the TSDR of Foxp3 with the efficacy and sustainability of EPIT, additional studies in ongoing clinical trials are required to confirm that similar epigenetic changes occur during EPIT in allergic patients and their relationship to adequate immune responses.
Finally, this methylation pattern is specifically observed following EPIT and not OIT in peanut-sensitized mice, supporting differences in the mechanisms of actions between the two immunotherapies. 7, 11 Taken together, we demonstrate in a model of peanut-sensitized 
